Bio-Rad Closes Acquisition of Dx QC Shop Blackhawk Biosystems | GenomeWeb
NEW YORK (GenomeWeb News) — Bio-Rad Laboratories today said it has closed its acquisition of Blackhawk Biosystems, a privately held maker of quality-control products for infectious disease testing.
 
Bio-Rad CEO Norman Schwartz said he expects this acquisition will help his company expand its online quality control and inter-laboratory peer group comparison.
 
Financial terms of the acquisition were not disclosed.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.